Skip to main content
Premium Trial:

Request an Annual Quote

Invitrogen, ABI Shareholders Approve Merger

NEW YORK (GenomeWeb News) – Invitrogen and Applied Biosystems announced separately today that their respective shareholders have voted in favor of the firms’ $6.7 billion merger.
 
Both firms said that around 98 percent of their respective shares were cast in favor of the deal, which is expected to close next month. The transaction already has cleared US antitrust hurdles but still requires clearance from European Union regulators.
 
As reported by GenomeWeb Daily News on Oct. 9, Invitrogen increased its expectations for first-year post-merger cost synergies to $80 million from $60 million. It said today that it remains committed to achieving that goal.
 
Invitrogen also said that the current issues affecting capital markets are not anticipated to have an impact on financing for the deal.

The Scan

Purnell Choppin Dies

Purnell Choppin, a virologist who led the Howard Hughes Medical Institute, has died at 91, according to the Washington Post.

Effectiveness May Decline, Data From Israel Suggests

The New York Times reports that new Israeli data suggests a decline in Pfizer-BioNTech SARS-CoV-2 vaccine effectiveness against Delta variant infection, though protection against severe disease remains high.

To See Future Risk

Slate looks into the use of polygenic risk scores in embryo screening.

PLOS Papers on Methicillin-Resistant Staphylococcus, Bone Marrow Smear Sequencing, More

In PLOS this week: genomic analysis of methicillin-resistant Staphylococcus pseudintermedius, archived bone marrow sequencing, and more.